There are more than 50,000 venture-backed startups in the U.S., and only the tiniest fraction will ever reach a $1 billion valuation. Here are the 25 we think most likely to succeed.
The market’s obsession with data science and artificial intelligence is reflected in this year’s list of 25 companies we think most likely to reach $1 billion valuation.
Not quite 18 months after being named CEO of Truepill, cofounder Sid Viswanathan is gone. The company, worth $1.6 billion at its last equity funding round, faces an uncertain future with a cash squeeze and DEA investigation.
Since the start of the pandemic, the popular medical device has been indispensable for measuring oxygen in the blood, but dangerously inaccurate in patients with darker skin. Now the FDA is in the hot seat and Black researchers are working on a cure.
Two of Indiana’s biggest employers said last month that they’d think twice about expanding facilities in the state after the legislature passed a near-total ban on abortion. A new poll shows that, nationwide, the companies are hardly unique.
Hospitals have long used ultraviolet light to zap viruses, but the devices were too expensive for business and schools. Spurred by the pandemic, an unlikely trio started R-Zero to develop a lower-cost alternative—and was just featured on our latest lis…